December 2017

Important New Products

• Intuniv (guanfacine (hydrochloride)) is a selective α2A-adrenergic receptor agonist. ...(more)
• Kisqali (ribociclib (succinate)) selectively inhibits cyclin dependent kinase (CDK) 4 and 6. ...(more)
• Monurol (fosfomycin (trometamol)) inhibits the phosphoenolpyruvate transferase enzyme, ...(more)
• Sativex (nabiximols) contains cannabinoid botanical drug substances (partially purified ...(more)
• Spinraza (nusinersen (heptadecasodium)) is an antisense oligonucleotide specifically ...(more)

New Indications

• Humira (adalimumab) is now indicated for the treatment of active moderate to severe ...(more)

New Contraindications

• Coadministration of Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) ...(more)
• Motilium (domperidone) is contraindicated with known existing prolongation of cardiac ...(more)
• Resprim, Resprim Forte (sulfamethoxazole/trimethoprim) should not be given to babies ...(more)
• Coadministration of Xatral SR (alfuzosin hydrochloride) with potent CYP3A4 inhibitors is ...(more)
• Coadministration of Zerit (stavudine) with didanosine is contraindicated due to the potential ...(more)

Active Ingredient Naming Changes

In this release, MIMS Australia will be including the following INNs (International Non-proprietary Names) as well as Australian Approved Names (AANs) as part of our push to support the Therapeutic Goods Administration (TGA) active ingredient name changes project.  

MIMS will begin referring to these ingredients by their new names, however, users may continue to search by the old AANs if preferred. ...(more)